MedPath

NOVACEA

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

10

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:5
Phase 2:4
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (50.0%)
Phase 2
4 (40.0%)
Phase 3
1 (10.0%)

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

First Posted Date
2007-09-28
Last Posted Date
2007-11-06
Lead Sponsor
Novacea
Target Recruit Count
132
Registration Number
NCT00536770
Locations
🇺🇸

Novacea Investigational Site, Nashville, Tennessee, United States

AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

Phase 1
Conditions
Glioblastoma Multiforme
First Posted Date
2006-11-01
Last Posted Date
2007-05-30
Lead Sponsor
Novacea
Target Recruit Count
60
Registration Number
NCT00394628
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

🇺🇸

Henry Ford Health Systems, Detroit, Michigan, United States

and more 2 locations

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Phase 2
Conditions
Androgen Independent Prostate Cancer (AIPC)
Non Small Cell Lung Cancer (NSCLC)
First Posted Date
2006-02-02
Last Posted Date
2006-05-31
Lead Sponsor
Novacea
Target Recruit Count
25
Registration Number
NCT00285675
Locations
🇺🇸

Alta Bates Comprehensive Cancer Center, Berkeley, California, United States

🇺🇸

Pacific Hematology Oncology Associates, San Francisco, California, United States

🇺🇸

Kaiser Permanente Medical Group, Northern California, Vallejo, California, United States

and more 10 locations

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Phase 3
Terminated
Conditions
Prostate Cancer
First Posted Date
2006-01-09
Last Posted Date
2007-11-06
Lead Sponsor
Novacea
Target Recruit Count
1200
Registration Number
NCT00273338
Locations
🇺🇸

Birmingham Hematology & Oncology Associates, LLC, Birmingham, Alabama, United States

🇺🇸

Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States

🇺🇸

Alaska Clinical Research Center, Anchorage, Alaska, United States

and more 209 locations

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

Phase 1
Conditions
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia
First Posted Date
2005-04-27
Last Posted Date
2007-05-07
Lead Sponsor
Novacea
Target Recruit Count
55
Registration Number
NCT00109356
Locations
🇺🇸

Weill Medical College of Cornell University/ New York Presbyterian Hospital, New York, New York, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath